Categories: News

cbdMD, Inc. to Host Conference Call to Discuss Third Quarter of Fiscal 2024 Results

Charlotte, North Carolina–(Newsfile Corp. – August 5, 2024) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation’s leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, August 14, 2024, to discuss the company’s June 30, 2024 third quarter of fiscal 2024 financial results and business progress.

CONFERENCE CALL DETAILS

Wednesday August 14, 2024, 4:20 p.m. Eastern Time
USA/Canada: 844-763-8274
International: 647-484-8814

Teleconference Replay dial in:
USA/Canada: 877-344-7529
International: 412-317-0088
Replay Passcode: 5067217
Webcast/Webcast Replay link – available through August 14, 2025:

https://www.gowebcasting.com/13431

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and recognized hemp-derived cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products as well as Full Spectrum and Delta 9 THC products. The cbdMD brand currently includes high-quality, premium CBD products including tinctures, gummies, topicals, capsules, sleep aids and more. The Company’s Paw CBD brand includes formulated pet products including tinctures, chews and topicals in varying strengths. cbdMD also operates ATRx Labs, a line of functional mushroom supplements. To learn more about cbdMD and the complete line of products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook or visit one of the thousands of retail outlets that carry cbdMD products.

1 THC-free is defined as below the level of detection using validated scientific analytical tools.

Contact Information:

cbdMD, Inc.
Ronan Kennedy, CEO
Phone: +1 (704) 445-3064 email: IR@cbdmd.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218832

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

3 hours ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

3 hours ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

3 hours ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

3 hours ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

3 hours ago